Secondary analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) indicate that CV and kidney function benefits are unlikely mediated by the glucose-lowering properties of the SGLT2 inhibitors (Inzucchi et al. 2018). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.